These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
352 related articles for article (PubMed ID: 35534562)
1. Meningioma DNA methylation groups identify biological drivers and therapeutic vulnerabilities. Choudhury A; Magill ST; Eaton CD; Prager BC; Chen WC; Cady MA; Seo K; Lucas CG; Casey-Clyde TJ; Vasudevan HN; Liu SJ; Villanueva-Meyer JE; Lam TC; Pu JK; Li LF; Leung GK; Swaney DL; Zhang MY; Chan JW; Qiu Z; Martin MV; Susko MS; Braunstein SE; Bush NAO; Schulte JD; Butowski N; Sneed PK; Berger MS; Krogan NJ; Perry A; Phillips JJ; Solomon DA; Costello JF; McDermott MW; Rich JN; Raleigh DR Nat Genet; 2022 May; 54(5):649-659. PubMed ID: 35534562 [TBL] [Abstract][Full Text] [Related]
2. Hypermitotic meningiomas harbor DNA methylation subgroups with distinct biological and clinical features. Choudhury A; Chen WC; Lucas CG; Bayley JC; Harmanci AS; Maas SLN; Santagata S; Klisch T; Perry A; Bi WL; Sahm F; Patel AJ; Magill ST; Raleigh DR Neuro Oncol; 2023 Mar; 25(3):520-530. PubMed ID: 36227281 [TBL] [Abstract][Full Text] [Related]
3. The role and regulatory mechanism of IL-1β on the methylation of the NF2 gene in benign meningiomas and leptomeninges. Wang B; Cui Z; Zhong Z; Sun Y; Yang GY; Sun Q; Bian L Mol Carcinog; 2016 Dec; 55(12):2268-2277. PubMed ID: 26840621 [TBL] [Abstract][Full Text] [Related]
4. YAP1-FAM118B Fusion Defines a Rare Subset of Childhood and Young Adulthood Meningiomas. Schieffer KM; Agarwal V; LaHaye S; Miller KE; Koboldt DC; Lichtenberg T; Leraas K; Brennan P; Kelly BJ; Crist E; Rusin J; Finlay JL; Osorio DS; Sribnick EA; Leonard JR; Feldman A; Orr BA; Serrano J; Vasudevaraja V; Snuderl M; White P; Magrini V; Wilson RK; Mardis ER; Boué DR; Cottrell CE Am J Surg Pathol; 2021 Mar; 45(3):329-340. PubMed ID: 33074854 [TBL] [Abstract][Full Text] [Related]
5. DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis. Sahm F; Schrimpf D; Stichel D; Jones DTW; Hielscher T; Schefzyk S; Okonechnikov K; Koelsche C; Reuss DE; Capper D; Sturm D; Wirsching HG; Berghoff AS; Baumgarten P; Kratz A; Huang K; Wefers AK; Hovestadt V; Sill M; Ellis HP; Kurian KM; Okuducu AF; Jungk C; Drueschler K; Schick M; Bewerunge-Hudler M; Mawrin C; Seiz-Rosenhagen M; Ketter R; Simon M; Westphal M; Lamszus K; Becker A; Koch A; Schittenhelm J; Rushing EJ; Collins VP; Brehmer S; Chavez L; Platten M; Hänggi D; Unterberg A; Paulus W; Wick W; Pfister SM; Mittelbronn M; Preusser M; Herold-Mende C; Weller M; von Deimling A Lancet Oncol; 2017 May; 18(5):682-694. PubMed ID: 28314689 [TBL] [Abstract][Full Text] [Related]
6. Advances in Molecular Classification and Therapeutic Opportunities in Meningiomas. Cordova C; Kurz SC Curr Oncol Rep; 2020 Jul; 22(8):84. PubMed ID: 32617743 [TBL] [Abstract][Full Text] [Related]
7. Clinical significance of NF2 alteration in grade I meningiomas revisited; prognostic impact integrated with extent of resection, tumour location, and Ki-67 index. Teranishi Y; Okano A; Miyawaki S; Ohara K; Ishigami D; Hongo H; Dofuku S; Takami H; Mitsui J; Ikemura M; Komura D; Katoh H; Ushiku T; Ishikawa S; Shin M; Nakatomi H; Saito N Acta Neuropathol Commun; 2022 May; 10(1):76. PubMed ID: 35570314 [TBL] [Abstract][Full Text] [Related]
12. Histone deacetylase inhibitor AR-42 differentially affects cell-cycle transit in meningeal and meningioma cells, potently inhibiting NF2-deficient meningioma growth. Burns SS; Akhmametyeva EM; Oblinger JL; Bush ML; Huang J; Senner V; Chen CS; Jacob A; Welling DB; Chang LS Cancer Res; 2013 Jan; 73(2):792-803. PubMed ID: 23151902 [TBL] [Abstract][Full Text] [Related]
13. Expression of NF2 gene product merlin in arachnoid villi and meningiomas. Sakuda K; Kohda Y; Matsumoto T; Park C; Seto A; Tohma Y; Hasegawa M; Kida S; Nitta H; Yamashima T; Yamashita J Noshuyo Byori; 1996 Nov; 13(2):145-8. PubMed ID: 8958521 [TBL] [Abstract][Full Text] [Related]
14. Expression of the tumor suppressor genes NF2, 4.1B, and TSLC1 in canine meningiomas. Dickinson PJ; Surace EI; Cambell M; Higgins RJ; Leutenegger CM; Bollen AW; LeCouteur RA; Gutmann DH Vet Pathol; 2009 Sep; 46(5):884-92. PubMed ID: 19429976 [TBL] [Abstract][Full Text] [Related]
15. Meningiomas induced by low-dose radiation carry structural variants of NF2 and a distinct mutational signature. Sahm F; Toprak UH; Hübschmann D; Kleinheinz K; Buchhalter I; Sill M; Stichel D; Schick M; Bewerunge-Hudler M; Schrimpf D; Zadeh G; Aldape K; Herold-Mende C; Beck K; Staszewski O; Prinz M; Harosh CB; Eils R; Sturm D; Jones DTW; Pfister SM; Paulus W; Ram Z; Schlesner M; Grossman R; von Deimling A Acta Neuropathol; 2017 Jul; 134(1):155-158. PubMed ID: 28474103 [No Abstract] [Full Text] [Related]
16. Crispr/Cas-based modeling of NF2 loss in meningioma cells. Waldt N; Kesseler C; Fala P; John P; Kirches E; Angenstein F; Mawrin C J Neurosci Methods; 2021 May; 356():109141. PubMed ID: 33753124 [TBL] [Abstract][Full Text] [Related]
17. Whole exome sequencing in a case of sporadic multiple meningioma reveals shared NF2, FAM109B, and TPRXL mutations, together with unique SMARCB1 alterations in a subset of tumor nodules. Torres-Martín M; Kusak ME; Isla A; Burbano RR; Pinto GR; Melendez B; Castresana JS; Rey JA Cancer Genet; 2015 Jun; 208(6):327-32. PubMed ID: 25981829 [TBL] [Abstract][Full Text] [Related]
18. Clinical potential of meningioma genomic insights: a practical review for neurosurgeons. Karsy M; Azab MA; Abou-Al-Shaar H; Guan J; Eli I; Jensen RL; Ormond DR Neurosurg Focus; 2018 Jun; 44(6):E10. PubMed ID: 29852774 [TBL] [Abstract][Full Text] [Related]
19. NF2 mutation status and tumor mutational burden correlate with immune cell infiltration in meningiomas. Rutland JW; Gill CM; Loewenstern J; Arib H; Pain M; Umphlett M; Kinoshita Y; McBride RB; Bederson J; Donovan M; Sebra R; Shrivastava RK; Fowkes M Cancer Immunol Immunother; 2021 Jan; 70(1):169-176. PubMed ID: 32661686 [TBL] [Abstract][Full Text] [Related]